| Bid | 1.4 |
| Market Cap | 167.06M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.09 |
| PE Ratio (ttm) | -16.11 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.55 |
| Volume | 2,108,460 |
| Avg. Volume (20D) | 5,060,686 |
| Open | 1.47 |
| Previous Close | 1.47 |
| Day's Range | 1.45 - 1.60 |
| 52-Week Range | 0.66 - 2.97 |
| Beta | undefined |
About CHRS
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma ...
Analyst Forecast
According to 4 analyst ratings, the average rating for CHRS stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 382.76% from the latest price.
Next Earnings Release
Analysts project revenue of $43.88M, reflecting a -52.06% YoY shrinking and earnings per share of -0.18, making a -70.97% decrease YoY.
1 month ago · seekingalpha.com
Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing DevelopmentCoherus BioSciences focuses on immunotherapy, expanding their PD-1 antibody market, and developing novel treatments for solid tumors, despite maintaining a penny stock valuation. Financially, CHRS hol...
